Neuraxpharm And Panaxia Take Cannabis Tablets To France
Comes Shortly After Panaxia Malta Facility Granted EU GMP Status
Executive Summary
Neuraxpharm and Panaxia have continued to push forward with their partnership on medical cannabis, exporting sublingual tablets to France as part of a pilot program organized by local regulator ANSM.
You may also be interested in...
Dr Reddy’s Continues To Capitalize On German Cannabinoids With MediCane Launch
Dr Reddy's has announced that it will market MediCane’s medical cannabis portfolio across Germany, as part of a collaboration between the two companies which began last year.
Neuraxpharm’s Brain Acquisition Stems From Expansion Ambitions
Privately-owned Neuraxpharm has found another company to give it further access to a new European market, picking up Athens-based Brain Therapeutics. It aims now to introduce its Buccolam (midazolam) in Greece.
Dr Reddy’s Steps Into 'Must-Be' Medical Cannabis Segment With German Deal
Dr Reddy’s enters high-potential medical cannabis fray with the acquisition of Nimbus Health in Germany. The segment has seen a flurry of activity over the recent past, including the $7.2bn acquisition of pioneer GW Pharmaceuticals.